Tuesday November 12, 2019
Home Lead Story China Success...

China Successfully Launches Rocket from Sailing Ship into Space

The two satellites are expected to step up all-weather monitoring of ocean wind fields, improve typhoon monitoring and accuracy of the weather forecast in China

0
//
US clothing brand Gap has apologised for selling T-shirts which it said showed an
Accurate Map of China. Pixabay

In a first, China on Wednesday successfully launched a rocket from a sailing ship into space, showcasing its prowess in the field.

A Long March-11 solid propellant carrier rocket blasted off at 12.06 p.m. from the mobile platform in the Yellow Sea off Shandong Province, Chinese news agency Xinhua reported.

It is China’s first space launch from a sea-based platform and the 306th mission of the Long March carrier rocket series, the state-owned news outlet said.

The Long March-11 can carry small satellites and can take multiple satellites into orbit at the same time.

xi jinping
China’s President Xi Jinping attends the closing session of the National People’s Congress (NPC) in Beijing’s Great Hall of the People on March 15, 2019. RFA

The rocket carried two technology experiment satellites and five commercial satellites into space.

“The seaborne launch technology will meet the growing launch demand of low inclination satellites and help China provide launch services for countries participating in the Belt and Road Initiative,” experts were quoted as saying by Xinhua.

Also Read- Alexa to Soon Plan Your Family Night, Including Dinner, Movie, and a Ride

The two satellites are expected to step up all-weather monitoring of ocean wind fields, improve typhoon monitoring and accuracy of the weather forecast in China. (IANS)

Next Story

China Okays Sale of First Home-Grown Drug for Treatment of Mild to Moderate Alzheimer’s Disease

A multi-centre global phase 3 clinical trial with sites in the US, Europe and Asia is planned to be initiated in early 2020

0
China, Home, Drug
Oligomannate will provide a new treatment option to fight Alzheimer's disease for patients and is expected to be available in China by the end of 2019, Green Valley Pharmaceutical said on Saturday. Pixabay

China has approved the first home-grown drug for the treatment of “mild to moderate Alzheimer’s disease (AD) and improving cognitive function”, according to its developers.

The new drug, Oligomannate (GV-971), is the first to be approved for Alzheimer’s disease globally since 2003, said Green Valley Pharmaceutical Co., which developed the drug along with Ocean University of China, Shanghai Institute of Materia Medica under Chinese Academy of Sciences.

Oligomannate will provide a new treatment option to fight Alzheimer’s disease for patients and is expected to be available in China by the end of 2019, Green Valley Pharmaceutical said on Saturday.

A multi-centre global phase 3 clinical trial with sites in the US, Europe and Asia is planned to be initiated in early 2020 to support global regulatory filing of Oligomannate.

China, Home, Drug
The new drug, Oligomannate (GV-971), is the first to be approved for Alzheimer’s disease globally since 2003, said Green Valley Pharmaceutical Co., which developed the drug along with Ocean University of China, Shanghai Institute of Materia Medica under Chinese Academy of Sciences. Pixabay

An effective treatment for Alzheimer’s that affects about 48 million people in the world could easily become a big hit globally.

China’s National Medical Products Administration granted Oligomannate fast-track review in November 2018.

Over 800 patients with the diagnosis of mild to moderate Alzhemer’s disease completed the Phase 3 clinical trial conducted in 34 tier-1 hospitals across China.

Results of the 36-week-long study showed that Oligomannate can improve cognitive function in mild-to-moderate Alzheimer’s disease patients as early as week 4 and the benefit was sustained at each follow-up assessment visit.

Also Read- Bengal Focuses on Alternatives after Banning Stubble Burning

Alzheimer’s disease is a progressive brain disorder that impairs memory, affecting the ability of patients to carry out simple tasks. (IANS)